NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell ...
Additional information on the poster presentation including session location and timing details will be made available by ASGCT via the ASGCT Annual Meeting conference program website in mid-April.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results